CIPLA
|
The Current P/E Ratio of CIPLA is 29.89.
| Share Price | ₹1,431.7 | Jul 08,2026 |
| Market Cap | ₹115,648.7 Cr | |
| Earnings-TTM | ₹3,869.8 Cr | TTM-Consolidated Results |
| Price/Earnings | 29.89x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of CIPLA
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹115,648.7 Cr] as on Jul 08,2026
(/) Earnings [ ₹3,869.8 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 29.89x ]
Thus, for CIPLA , the investors are currently willing to pay 29.89 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of CIPLA !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of CIPLA over the last five years.
Historical PE (Price/Earnings) ratio chart of CIPLA
PE Ratio Performance Analysis for CIPLA
- CIPLA 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 27.09x.
- CIPLA 's operated at median p/e ratio of 25.95x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, CIPLA 's p/e ratio peaked in Mar2022 at 32.65x.
- CIPLA 's p/e ratio hit its five-year low in Mar2025 of 22.08x.
How does CIPLA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| CIPLA | 3,869.79 | 29.89 | 115,648.7 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,564.50 | 39.17 | 452,982.0 |
| DIVIS LABORATORIES LTD | 2,568.00 | 69.84 | 179,361.0 |
| TORRENT PHARMACEUTICALS LTD | 2,138.00 | 77.05 | 164,737.0 |
| DR REDDYS LABORATORIES LTD | 4,144.20 | 27.16 | 112,573.0 |
| MANKIND PHARMA LTD | 1,926.41 | 53.36 | 102,795.0 |
| LUPIN LTD | 5,355.47 | 20.98 | 112,363.0 |
| ZYDUS LIFESCIENCES LTD | 5,026.40 | 22.80 | 114,613.0 |
| AUROBINDO PHARMA LTD | 3,501.45 | 25.58 | 89,580.6 |
| LAURUS LABS LTD | 889.85 | 89.23 | 79,403.2 |
| BIOCON LTD | 368.80 | 175.39 | 64,682.6 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs CIPLA 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 20.98x |
| Max industry PE | 175.39x |
| Median industry PE | 39.17x |
| Average industry PE | 57.32x |
You may also like the below Video Courses